Amgen annual revenue
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Amgen Revenue Growth & History (AMGN)
Amgen reported $36.75B in revenue for fiscal 2025, an increase of 9.95% from the previous fiscal year.
View full Amgen company overviewAmgen annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $36.75B | $3.33B | +9.95% |
| 2024 | 2024-12-31 | $33.42B | $5.23B | +18.57% |
| 2023 | 2023-12-31 | $28.19B | $1.87B | +7.09% |
| 2022 | 2022-12-31 | $26.32B | $344.0M | +1.32% |
| 2021 | 2021-12-31 | $25.98B | $555.0M | +2.18% |
| 2020 | 2020-12-31 | $25.42B | $2.06B | +8.83% |
| 2019 | 2019-12-31 | $23.36B | −$385.0M | −1.62% |
| 2018 | 2018-12-31 | $23.75B | $898.0M | +3.93% |
| 2017 | 2017-12-31 | $22.85B | −$142.0M | −0.62% |
| 2016 | 2016-12-31 | $22.99B | $1.33B | +6.14% |
| 2015 | 2015-12-31 | $21.66B | $1.60B | +7.97% |
| 2014 | 2014-12-31 | $20.06B | $1.39B | +7.43% |
| 2013 | 2013-12-31 | $18.68B | $1.41B | +8.17% |
| 2012 | 2012-12-31 | $17.27B | $1.68B | +10.80% |
| 2011 | 2011-12-31 | $15.58B | $529.0M | +3.51% |
| 2010 | 2010-12-31 | $15.05B | $411.0M | +2.81% |
| 2009 | 2009-12-31 | $14.64B | −$361.0M | −2.41% |
| 2008 | 2008-12-31 | $15.00B | $232.0M | +1.57% |
| 2007 | 2007-12-31 | $14.77B | — | — |
Amgen quarterly revenue
Q2.08
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $10.05B | $875.0M | +9.53% |
| Q1 2026 | 2026-03-31 | $8.62B | $469.0M | +5.76% |
| Q4 2025 | 2025-12-31 | $9.87B | $780.0M | +8.58% |
| Q3 2025 | 2025-09-30 | $9.56B | $1.05B | +12.40% |
| Q2 2025 | 2025-06-30 | $9.18B | $791.0M | +9.43% |
| Q1 2025 | 2025-03-31 | $8.15B | $702.0M | +9.43% |
| Q4 2024 | 2024-12-31 | $9.09B | $890.0M | +10.86% |
| Q3 2024 | 2024-09-30 | $8.50B | $1.60B | +23.18% |
| Q2 2024 | 2024-06-30 | $8.39B | $1.40B | +20.07% |
| Q1 2024 | 2024-03-31 | $7.45B | $1.34B | +21.98% |
| Q4 2023 | 2023-12-31 | $8.20B | $1.36B | +19.84% |
| Q3 2023 | 2023-09-30 | $6.90B | $251.0M | +3.77% |
| Q2 2023 | 2023-06-30 | $6.99B | $392.0M | +5.94% |
| Q1 2023 | 2023-03-31 | $6.11B | −$133.0M | −2.13% |
| Q4 2022 | 2022-12-31 | $6.84B | −$7.0M | −0.10% |
| Q3 2022 | 2022-09-30 | $6.65B | −$54.0M | −0.81% |
| Q2 2022 | 2022-06-30 | $6.59B | $68.0M | +1.04% |
| Q1 2022 | 2022-03-31 | $6.24B | $337.0M | +5.71% |
| Q4 2021 | 2021-12-31 | $6.85B | $212.0M | +3.20% |
| Q3 2021 | 2021-09-30 | $6.71B | $283.0M | +4.41% |
| Q2 2021 | 2021-06-30 | $6.53B | $320.0M | +5.16% |
| Q1 2021 | 2021-03-31 | $5.90B | −$260.0M | −4.22% |
| Q4 2020 | 2020-12-31 | $6.63B | $437.0M | +7.05% |
| Q3 2020 | 2020-09-30 | $6.42B | $686.0M | +11.96% |
| Q2 2020 | 2020-06-30 | $6.21B | $335.0M | +5.71% |
| Q1 2020 | 2020-03-31 | $6.16B | $604.0M | +10.87% |
| Q4 2019 | 2019-12-31 | $6.20B | −$33.0M | −0.53% |
| Q3 2019 | 2019-09-30 | $5.74B | −$167.0M | −2.83% |
| Q2 2019 | 2019-06-30 | $5.87B | −$188.0M | −3.10% |
| Q1 2019 | 2019-03-31 | $5.56B | $3.0M | +0.05% |
| Q4 2018 | 2018-12-31 | $6.23B | $661.0M | +11.87% |
| Q3 2018 | 2018-09-30 | $5.90B | $131.0M | +2.27% |
| Q2 2018 | 2018-06-30 | $6.06B | $249.0M | +4.29% |
| Q1 2018 | 2018-03-31 | $5.55B | $90.0M | +1.65% |
| Q4 2017 | 2017-12-31 | $5.57B | −$94.0M | −1.66% |
| Q3 2017 | 2017-09-30 | $5.77B | −$38.0M | −0.65% |
| Q2 2017 | 2017-06-30 | $5.81B | $122.0M | +2.14% |
| Q1 2017 | 2017-03-31 | $5.46B | −$63.0M | −1.14% |
| Q4 2016 | 2016-12-31 | $5.66B | $334.0M | +6.27% |
| Q3 2016 | 2016-09-30 | $5.81B | $88.0M | +1.54% |
| Q2 2016 | 2016-06-30 | $5.69B | $318.0M | +5.92% |
| Q1 2016 | 2016-03-31 | $5.53B | $494.0M | +9.82% |
| Q4 2015 | 2015-12-31 | $5.33B | −$2.0M | −0.04% |
| Q3 2015 | 2015-09-30 | $5.72B | $692.0M | +13.75% |
| Q2 2015 | 2015-06-30 | $5.37B | $190.0M | +3.67% |
| Q1 2015 | 2015-03-31 | $5.03B | $512.0M | +11.32% |
| Q4 2014 | 2014-12-31 | $5.33B | $532.0M | +11.09% |
| Q3 2014 | 2014-09-30 | $5.03B | $283.0M | +5.96% |
| Q2 2014 | 2014-06-30 | $5.18B | $501.0M | +10.71% |
| Q1 2014 | 2014-03-31 | $4.52B | $283.0M | +6.68% |
| Q4 2013 | 2013-12-31 | $4.80B | $462.0M | +10.65% |
| Q3 2013 | 2013-09-30 | $4.75B | $429.0M | +9.93% |
| Q2 2013 | 2013-06-30 | $4.68B | $202.0M | +4.51% |
| Q1 2013 | 2013-03-31 | $4.24B | $190.0M | +4.69% |
| Q4 2012 | 2012-12-31 | $4.34B | $430.0M | +11.01% |
| Q3 2012 | 2012-09-30 | $4.32B | $375.0M | +9.51% |
| Q2 2012 | 2012-06-30 | $4.48B | $518.0M | +13.08% |
| Q1 2012 | 2012-03-31 | $4.05B | $342.0M | +9.23% |
| Q4 2011 | 2011-12-31 | $3.91B | $147.0M | +3.91% |
| Q3 2011 | 2011-09-30 | $3.94B | $128.0M | +3.35% |
| Q2 2011 | 2011-06-30 | $3.96B | $155.0M | +4.07% |
| Q1 2011 | 2011-03-31 | $3.71B | $114.0M | +3.17% |
| Q4 2010 | 2010-12-31 | $3.76B | $17.0M | +0.45% |
| Q3 2010 | 2010-09-30 | $3.82B | $4.0M | +0.10% |
| Q2 2010 | 2010-06-30 | $3.80B | $91.0M | +2.45% |
| Q1 2010 | 2010-03-31 | $3.59B | $284.0M | +8.59% |
| Q4 2009 | 2009-12-31 | $3.74B | — | — |
| Q3 2009 | 2009-09-30 | $3.81B | −$63.0M | −1.63% |
| Q2 2009 | 2009-06-30 | $3.71B | −$51.0M | −1.35% |
| Q1 2009 | 2009-03-31 | $3.31B | — | — |
| Q3 2008 | 2008-09-30 | $3.88B | — | — |
| Q2 2008 | 2008-06-30 | $3.76B | — | — |
Amgen revenue growth trends
Over the last five reported fiscal years, revenue grew from $25.42B to $36.75B, a compound annual growth rate of 7.65%. Amgen's latest reported quarter, Q2 2026, generated $10.05B in revenue, an increase of 9.53% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Amgen source filings ↗